Back
About the Global Fund
People & Structures
Back
Funding Model
Investments & Results
-
Explore contributions, investments and results in our fight against AIDS, tuberculosis and malaria around the world.
- Data Explorer
- Funding Decisions
- Data Service
HIV & AIDS
Tuberculosis
Malaria
Back
News
-
18 November 2020
Lao PDR aims to achieve universal health coverage with new Global Fund, Government of Australia and World Bank investment -
12 November 2020
Germany signs EUR150 million contribution to the Global Fund’s COVID-19 response -
12 November 2020
Global Fund Board signals strong commitment to sustain the fight against HIV, TB, malaria while supporting the global response to COVID-19 -
05 October 2020
Global Fund and Chevron: United Against HIV, TB and Malaria
Updates
-
20 November 2020
Opportunity for Evaluation of Selected Medicines -
19 November 2020
Lusophone TB Caucus launched alongside a new Lusophone Impact Report -
18 November 2020
Lao PDR aims to achieve universal health coverage with new Global Fund, Government of Australia and World Bank investment -
12 November 2020
Germany signs EUR150 million contribution to the Global Fund’s COVID-19 response
Stories
-
19 November 2020
Why drug-resistant tuberculosis poses a major risk to global health security -
19 November 2020
COVID-19 must transform the definition of global health security -
13 November 2020
Aftab’s Story: Fighting TB in the Shadow of COVID-19 in India -
13 November 2020
Behind the COVID-19 vaccines is a hidden arsenal of diagnostic tests -
13 November 2020
In Nigeria, health workers tackle stigma and misconceptions as they fight TB and COVID-19 -
09 November 2020
Living through lockdown
Back
Featured Publication
Documents by type
Opportunity for Evaluation of Selected Medicines
20 November 2020
The Global Fund, Stop TB Partnership Global Drug Facility and Unitaid are inviting manufacturers of antiretroviral (HIV/AIDS), antihepatitis B and C, antituberculosis and antimalarial medicines to submit an expression of interest to have their products evaluated by the Expert Review Panel for Pharmaceutical Products.
Detailed information about the review process and submission requirements for this Round 23 opportunity can be found in the document below.
Once all expressions of interest have been received, the Expert Review Panel will be responsible for reviewing and judging their eligibility and whether to perform a risk-benefit assessment of the products submitted.
The deadline for submission of an expression of interest is Friday 08 January 2021 (COB). At the end of January 2021, the Global Fund Secretariat will communicate to manufacturers the outcomes of the review of the completeness of documents submitted. The results of the product evaluations are expected for release by the end of March 2021.
- Invitation to Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial Medicines Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical ProductsInvitation to Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial Medicines Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products
download in English
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.